The poor therapeutic response towards targeted therapies in metastatic ERBB2+ BC is attributed in part to clonal evolution in metastatic cells, their adaptation to the organ-specific microenvironment, and differential drug delivery to the metastatic niche [4,5,6]. The gene discussed is ERBB2; the disease is breast cancer.